The effect of adding intrathecal magnesium sulphate to bupivacaine-fentanyl spinal anesthesia
A meta-analysis of randomized controlled trials
Jingguo Wang, MD, PhD, Zaitang Wang, MD, Bo Shi, MD, Na Wang, MD, PhD

Abstract
Trial design: The current study is a meta-analysis designed to assess the effect of adding magnesium to a combination of intrathecal bupivacaine and fentanyl.

Methods: The protocol was registered in PROSPERO with the number CRD42020177618. PubMed, Cochrane library, Web of Science, and Google Scholar were searched for randomized controlled trials investigating the effect of adding magnesium to a combination of intrathecal bupivacaine and fentanyl. The continuous data were presented as Ratio of means (RoM). Risk ratio (RR) along with 95% confidence interval (CI) was utilized to assess the dichotomous data.

Results: Ten trials were involved in the present study with 720 adult patients. Compared with control, intrathecal magnesium prolonged time to the first analgesic requirement by an estimate of 1.23 (RoM: 1.23; 95%CI: 1.13–1.33; P < .00001), prolonged adequate sensory block duration for surgery by an estimate of 1.16 (RoM: 1.16; 95%CI: 1.05–1.27; P = .003), delayed time to maximum sensory level by an estimate of 1.38 (RoM: 1.38; 95%CI: 1.07–1.78; P = .01) and reduced the incidence of shivering following spinal anesthesia (risk ratio: 0.38; 95%CI: 0.18 to 0.81, P = .01) without influence on time to full motor recovery or incidences of hypotension, bradycardia, nausea, and vomiting or pruritis.

Conclusion: Intrathecal magnesium, when added to a combination of intrathecal bupivacaine and fentanyl, prolongs the analgesic duration of spinal anesthesia without increased incidences of side effects.

Abbreviations: CI = confidence interval, NMDA = N-methyl D-aspartate, RCT = randomized controlled trials, RoM = ratio of means, RR = relative risk.

Keywords: bupivacaine, fentanyl, magnesium sulphate, meta-analysis, spinal anesthesia

1. Introduction
Effective treatment of perioperative pain is important because it can blunt stress reaction, and then lead to a decreased perioperative morbidity.[1] Research continues on techniques and medicines that could provide optimal operative conditions and postoperative pain relief. Various medicines such as opiates, benzodiazepines, the N-methyl D-aspartate (NMDA) receptor antagonists, α2 agonists etc, have been used clinically as adjuvants in spinal anesthesia.

The use of small dose of opioid combined with nonopioid drug as adjuvant to local anesthetic in spinal anesthesia is becoming increasingly popular for perioperative pain management. Surgical stimuli can activate NMDA receptors, which are involved in central sensitization.[2-3] Magnesium, a kind of NMDA receptor antagonist, can block NMDA channels in a voltage-dependent way, and the addition of magnesium can reduce NMDA-induced currents.[4] Therefore, magnesium has antinociceptive effect and has application in spinal anesthesia.

There are an increasing number of papers suggesting that intrathecal magnesium added to bupivacaine-fentanyl spinal anesthesia can improve the anesthetic effect. However, the relative data are inconsistent. Therefore, this meta-analysis is conducted to investigate the effect of adding magnesium to a combination of intrathecal bupivacaine and fentanyl.

2. Methods
2.1. Search strategy
Neither ethical approval nor informed consent was necessary, since it was a systematic review and meta-analysis. The present study was conducted following the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) recommendations.\[5\] The protocol was registered in PROSPERO with the number CRD42020177618. Randomized controlled trials (RCTs) investigating the effect of adding magnesium to a combination of intrathecal bupivacaine and fentanyl were selected and reviewed.

2.2. Study selection

The literature search was performed by two reviewers in PubMed, Web of Science, Cochrane library, and Google Scholar independently.

The literature search was performed by using the MESH and keywords including: “magnesium”, “fentanyl”, “anesthesia, spinal”, “injection, spinal” and “injection, subarachnoid” without language limitation. We manually searched the reference lists of related papers to find additional eligible RCTs. The latest search was done on March 20, 2020.

RCTs investigating the efficacy of adding magnesium to a combination of intrathecal bupivacaine and fentanyl were sought. The literature research was limited to human studies of subjects aged equal to or more than 18 years. Meeting papers, correspondences or editorials were excluded. If an agreement could not be reached between these 2 reviewers, the opinion of a third reviewer was obtained.

2.3. Quality and risk of bias assessment

The risk of bias and the quality of RCTs were separately evaluated using the Cochrane Collaboration Risk of Bias tool and a 5 point Jadad scale by 2 of the reviewers.\[6,7\] A score less than 3 was taken as low methodological quality. The third reviewer was consulted when an agreement could not be reached.

2.4. Data extraction

Data collection was performed by 2 authors. If an agreement could not be achieved, a third reviewer joined to make a decision. Extracted data included authors, publication year, surgery setting, sample size, dosages of bupivacaine, and fentanyl for spinal anesthesia, magnesium dose, as well as data on block characteristics.

2.5. Statistical analysis

Review Manager 5.3 (Cochrane Library, Oxford, England) was utilized for statistical analysis. Because of significant clinical heterogeneity of doses of bupivacaine, fentanyl and magnesium, ratio of means (RoM), standard error, and 95% confidence intervals (CIs) were calculated for continuous data to assess change from baseline for continuous data, under the assumption of equal variances in log scale and log-normal distribution.\[8–11\] Dichotomous data were analyzed using risk ratio (RR) and CIs. Statistical significance was considered if \( P \) value was <.05.

3. Results

3.1. Literature search

Of 165 initial papers found, 149 papers were excluded after screening. Sixteen full-text articles were found and assessed in detail, then 10 RCTs including 720 adult patients were eligible in this meta-analysis.\[12–21\] The detailed flowchart of the selection was presented in Figure 1.

3.2. Study characteristics

The details of the eligible RCTs were shown in Table 1. Intrathecal bupivacaine was used in all included trials, and the range of bupivacaine dosages used was 6 to 15 mg. The dosages of fentanyl combined with bupivacaine ranged from 10 to 25 mg. With the exception of one study\[12\] that used a 100 mg dose of magnesium sulphate, 50 mg magnesium was used in each of the reviewed trials.\[13–21\] The risk-of-bias plot was detailed in Figure 2.

3.3. Time to the first analgesic requirement

The primary outcome was time to the first analgesic requirement which was considered as time period from intrathecal injection to the first analgesic request. Nine studies reported time to the first analgesic requirement.\[12–20\] Intrathecal magnesium prolonged time to the first analgesic requirement by an estimate of 1.23 (RoM: 1.23; 95% CI: 1.13–1.33; \( P < .00001; I^2 = 96% \)) compared with control. (Fig. 3) Sensitivity analysis was conducted by removing each study individually. The reliability of the results was confirmed and no source of heterogeneity was found.

3.4. Time to maximum sensory level

Six studies evaluated time to maximum sensory level.\[13–17,21\] Intrathecal magnesium delayed time to maximum sensory level by an estimate of 1.38 (RoM: 1.38; 95% CI: 1.07–1.78; \( P = .01 \);

Figure 1. The flow chart of study selection.
### Table 1
Characteristics of the included randomized controlled trials.

| Author          | Date  | Jadad score | Dosage of intrathecal magnesium | Sample size M/C | Patient age | ASA status | Surgical setting | Local anesthetics for spinal anesthesia                     | Outcomes measures |
|-----------------|-------|-------------|---------------------------------|-----------------|-------------|------------|------------------|-------------------------------------------------------------|-------------------|
| Dayi et al. 2009 | 2009  | 4           | 50 mg                           | 30/30           | M: 41.2 ± 15.3 C: 38.7 ± 14.4 | I-II       | Elective knee arthroscopy | 6 mg 0.5% hyperbaric bupivacaine and 10 μg fentanyl      | 2, 6, 7, 8, 10 |
| Vishnuvarthan    | 2016  | 3           | 50 mg                           | 30/30           | 20–60 yr    | I-II       | Elective lower abdominal or lower limb surgeries | 12.5 mg 0.5% hyperbaric bupivacaine and 25 μg fentanyl    | 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 |
| Murugesan 2016   | 2016  | 3           | 50 mg                           | 35/35           | 20–65 yr    | I-II       | Elective lower extremity surgeries | 10 mg 0.5% bupivacaine and 0.5 ml fentanyl               | 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 |
| Dori 2016        | 2016  | 4           | 50 mg                           | 70/70           | 18–40 yr    | I-II       | Tibial fracture surgery | 10 mg bupivacaine and 25 μg fentanyl                        | 4, 7, 8           |
| Attari 2016      | 2016  | 4           | 50 mg                           | 35/35           | 20–65 yr    | I-II       | Elective lumbar disk herniation surgery | 15 mg 0.5% hyperbaric bupivacaine and 25 μg fentanyl | 1, 4, 6, 8, 10 |
| Rana 2017        | 2017  | 5           | 50 mg                           | 30/30           | M: 27.33 ± 3.85 C: 25.33 ± 3.70 | I-II       | Elective caesarean section | 8.5 mg 0.5% hyperbaric bupivacaine and 20 μg fentanyl | 1, 4, 6, 7       |
| Nath 2012        | 2012  | 4           | 100 mg                          | 30/30           | 18–60 yr    | I-II       | Total abdominal hysterectomy | 12.5 mg hyperbaric bupivacaine and 25 μg fentanyl | 1, 4, 6, 7, 8, 9, 10 |
| Vasure 2016      | 2016  | 5           | 50 mg                           | 20/20           | 20–50 yr    | I-II       | Elective lower limb orthopedic surgery | 12.5 mg 0.5% bupivacaine and 25 μg fentanyl | 1, 2, 3, 4, 6, 8, 9, 10 |
| Ayman 2018       | 2018  | 3           | 50 mg                           | 30/30           | 18–60 yr    | I-II       | Lower limb orthopedic surgeries | 12.5 mg hyperbaric bupivacaine and 25 μg fentanyl | 1, 2, 3, 4, 6, 7, 8, 9, 10 |
| Özlüevli 2005    | 2005  | 5           | 50 mg                           | 50/50           | M:38.3 ±1.5 C:38.4 ±7.6 | I-II       | Lower extremity surgery | 10 mg 0.5% bupivacaine and 25 μg fentanyl | 1, 2, 3, 4, 6, 7, 8, 9, 10 |

M = magnesium, C = control. ASA = American Society of Anesthesiologists. 1 = onset of sensory blockade, 2 = time to reach maximum sensory level, 3 = two-segment regression time, 4 = first analgesic request, 5 = onset of motor blockade, 6 = time to full motor recovery, 7 = hypotension and bradycardia, 8 = nausea and vomiting, 9 = shivering, 10 = pruritus.
I^2 = 97%) compared with control (Fig. 4). Sensitivity analysis was conducted by removing each study individually. The reliability of the results was confirmed and no source of heterogeneity was found.

3.5. Adequate sensory block duration

Adequate sensory block duration for surgery was defined as two segment regression time in 5 RCTs\(^\text{13–17}\) and defined as time to T10 regression in 2 RCTs.\(^\text{18,19}\) Therefore, adequate sensory block duration for surgery was assessed in 7 trials.\(^\text{13–19}\) Intrathecal magnesium prolonged adequate sensory block duration by an estimate of 1.16 (RoM: 1.16; 95%CI: 1.05–1.27; \(P = .003, I^2 = 93\%\)) compared with control. (Fig. 5) Sensitivity analysis was conducted by removing each study individually. The reliability of the results was confirmed and no source of heterogeneity was found.

3.6. Time to full motor recovery

The effect of intrathecal magnesium on time to full motor recovery was described in 8 studies reviewed. No significant difference was found in time to full motor recovery between the magnesium group and the control group (RoM: 1.07; 95%CI: 0.99–1.16; \(P = .11, I^2 = 93\%\)). (Fig. 6) Sensitivity analysis was conducted by removing each study individually. The reliability of the results was confirmed and no source of heterogeneity was found.

3.7. The incidence of hypotension and bradycardia

Seven studies\(^\text{12,13,15,17,19–21}\) reported the incidence of hypotension and 5 studies\(^\text{12,13,17,20,21}\) reported the incidence of bradycardia. For \(I^2 = 0\%\), the fixed effect model was used for meta-analysis. Our study demonstrated that intrathecal magnesium did not increase the incidence of hypotension (RR: 0.98; 95%CI: 0.70–1.37, \(P = .91; I^2 = 0\%\)) (Fig. 7A) and bradycardia (RR: 0.78; 95%CI: 0.44 to 1.39, \(P = .40; I^2 = 0\%\); Fig. 7B), compared with control.

3.8. The incidence of nausea and vomiting

The incidence of nausea and vomiting was reported in all but 1 study.\(^\text{19}\) The result showed the difference was not statistically significant in the incidence of nausea and vomiting between the
magnesium group and the control group (RR: 0.90; 95% CI: 0.56 to 1.46, \(P = 0.68\); \(I^2 = 0\%\)). (Fig. 8)

3.9. The incidence of shivering

The incidence of shivering following spinal anesthesia was assessed in 5 trials,\(^{12,13,15-17}\) permitting quantitative analysis. Intrathecal magnesium was associated with lower incidence of shivering following spinal anesthesia (RR: 0.38; 95% CI: 0.18–0.81, \(P = 0.01\); \(I^2 = 0\%\)). (Fig. 9)

3.10. The incidence of pruritis

The incidence of pruritis was assessed in 8 trials.\(^{12-18,21}\) Compared to placebo, no significant association of intrathecal magnesium with pruritis was found (RR: 0.89; 95% CI: 0.54 to 1.47, \(P = 0.65\); \(I^2 = 0\%\)). (Fig. 10)

4. Discussion

This meta-analysis demonstrates that addition of intrathecal magnesium is valuable for patients under bupivacaine-fentanyl spinal anesthesia.

The results of this meta-analysis indicate that intrathecal magnesium, when added to a combination of intrathecal bupivacaine and fentanyl, prolongs time to the first analgesic requirement and adequate sensory block duration for surgery, leads to a significant delay in time to maximum sensory level, and reduces the incidence of post-spinal anesthesia shivering.
addition, intrathecal magnesium sulfate does not influence time to full motor recovery or increase the incidences of hypotension, bradycardia, nausea, and vomiting or pruritis. Magnesium sulfate is a kind of NMDA receptor antagonist. This prolongation of sensory block resulting from intrathecal magnesium is due to synergistic interaction between intrathecal local anesthetics and NMDA antagonists. Magnesium sulfate can be used as an adjuvant for intrathecal block, because it can diminish neuronal excitation caused by activation of C-fibres.[22]

There are evidences suggesting that activation of the NMDA receptors is involved in both hyperalgesia after tissue injury and the development of central sensitization.[23] NMDA receptor antagonists can not only inhibit central sensitization caused by peripheral pain stimulation, but also blunt such hypersensitivity if it is formed up.[24]

The safety of intrathecal magnesium has been assessed in rat and canine studies, and no neurological deficit or histopathological change is observed after intrathecal magnesium administration.[25] In this meta-analysis, there are no serious complications associated with intrathecal magnesium reported in the included 10 RCTs.[12–21] Therefore, magnesium seems to be safe for intrathecal administration.

This meta-analysis has 2 limitations. First, statistical heterogeneity is high for some outcomes, making combination of the RCTs debatable, because of various outcome measures among the eligible RCTs. Second, we use the RoM method with
assumption of equal variances and lognormal distributions. The assumption is acceptable but can not be absolutely confirmed as lacking of individual patient’s data.[10]

5. Conclusion
Intrathecal magnesium, when added to a combination of intrathecal bupivacaine and fentanyl, prolongs the analgesic duration of spinal anesthesia, without increased incidences of side effects.

Author contributions
XXX.

References
[1] Sirvinskas E, Laurinaitis R. Use of magnesium sulphate in anesthesiology. Medicina 2002;38:695–8.
[2] Woolf CJ, Thompson SW. The induction and maintenance of central sensitization is dependent on N-methyl D-aspartic acid receptor activation: implications for the treatment of post-injury pain and hypersensitivity states. Pain 1991;44:293–9.
[3] Woolf CJ, Chong MS. Preemptive analgesia: treating postoperative pain by preventing the establishment of central sensitization. Anesth Analg 1993;77:362–79.
[4] Ascher P, Nowak L. Electrophysiological studies of NMDA receptors. Trends Neurosci 1987;10:284–8.
[5] Moher D, Liberati A, Tetzlaff J, et al. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264–9.
[6] Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration 2011; version 5.1.0. Available at: www.cochrane-handbook.org.
[7] Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1–2.
[8] Friedrich JO, Adhikari NK, Beyene J. The ratio of means method as an alternative to mean differences for analyzing continuous outcome variables in meta-analysis: a simulation study. BMC Med Res Methodol 2008;8:32.
[9] Friedrich JO, Adhikari NK, Beyene J. Ratio of means for analyzing continuous outcomes in meta-analysis performed as well as mean difference methods. J Clin Epidemiol 2011;64:556–64.
[10] Chang KV, Wu WT, Han DS, et al. Ulnar nerve cross-sectional area for the diagnosis of cubital tunnel syndrome: a meta-analysis of ultrasonographic measurements. Arch Phys Med Rehabil 2018;99:743–57.
[11] Chang KV, Wu WT, Hung CY, et al. Comparative effectiveness of suprascapular nerve block in the relief of acute post-operative shoulder pain: a systematic review and meta-analysis. Pain Physician 2016;19:445–56.
[12] Nath MP, Garg R, Talakdar T, et al. To evaluate the efficacy of intrathecal magnesium sulphate for hysterectomy under subarachnoid block with bupivacaine and fentanyl: A prospective randomized double blind clinical trial. Saudi J Anaesth 2012;6:254–8.
[13] Vishnuvardhan V, Hemalatha S, Sarika MS, et al. Effects of adding intrathecal magnesium sulphate to bupivacaine and fentanyl in lower abdominal and lower limb surgeries. IOSR J Dental Med Sci 2016;15:44–8.
[14] Murugesan BS, Ramakrishnan CD. The effect of adding intrathecal magnesium sulphate to bupivacaine-fentanyl spinal anaesthesia. J Evolution Med Dent 2016;5:7185–91.
[15] Ayman AM, Moustafa A, Sayed MA. Comparison between 3 different doses of magnesium sulphate as a spinal adjuvant to bupivacaine and fentanyl combination in lower limb orthopedic surgery. Med J Cairo Univ 2018;86:3253–62.
[16] Vasure R, Ashahiya ID, Mahendra R, et al. Comparison of effect of adding intrathecal magnesium sulfate to bupivacaine alone and bupivacaine-fentanyl combination during lower limb orthopedic surgery. Int J Sci Study 2016;3:141–6.

[17] Özalevli M, Cetin TO, Unlugenc H, et al. The effect of adding intrathecal magnesium sulphate to bupivacaine-fentanyl spinal anaesthesia. Acta Anaesthesiologica Scandinavica 2005;49:1514–9.

[18] Attari MA, Najafabadi FM, Talakoob R, et al. Comparison of the effects of 3 methods of intrathecal bupivacaine, bupivacaine-Fentanyl, and bupivacaine-fentanyl-magnesium sulfate on sensory motor blocks and postoperative pain in patients undergoing lumbar disk herniation surgery. J Neurosurg Anesthesiol 2016;28:38–43.

[19] Rana S, Singha D, Kumar S, et al. Efficacy of magnesium sulphate and/or fentanyl as adjuvants to intrathecal low-dose bupivacaine in parturients undergoing elective caesarean section. J Obstet Anaesth Crit Care 2017;7:20–5.

[20] Dori MM, Foruzin F. The analgesic efficacy of intrathecal bupivacaine and fentanyl with added neostigmine or magnesium sulphate. Anesth Pain Med 2016;6:e9651.

[21] Davroolu H, Baykara ZN, Salbes A, et al. Effects of adding Magnesium to bupivacaine and fentanyl for spinal anesthesia in knee arthroscopy. J Anesth 2009;23:19–25.

[22] Dickerson AH. NMDA receptor antagonists: interaction with opioids. Acta Anaesthesiol Scand 1997;41:112–5.

[23] Mao J, Price DD, Mayer DJ. Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain 1995;62:239–74.

[24] Ascher P, Nowak L. Electrophysiological studies of NMDA receptors. Trends Neurosci 1987;10:284–8.

[25] Simpson JI, Eide TR, Schiff GA. Intrathecal magnesiumsulfate protects the spinal cord from ischemic injury during thoracic aortic cross clamping. Anesthesiology 1994;81:1493–9.